Why Sangamo Biosciences, Inc. Trounced the Market

Shares of Sangamo Biosciences (NASDAQ: SGMO  ) are up more than 20% today on the news that HIV patients who were given Bristol-Myers Squibb's (NYSE: BMY  ) drug Cytoxan responded better to Sangamo's drug SB-728-T, which is made up of the patient's own genetically modified cells.

However, in this video, Motley Fool health-care analyst David Williamson points to a few things that investors need to keep in mind that should temper some of the enthusiasm. Firstly, the success story here was only two patients, and secondly, with Sangamo's drug, the virus is stabilized, but still detectable. Comparing this against current anti-viral drugs, which bring the virus down to undetectable levels, means Sangamo will still need to do better if it wants patients to switch. David takes a close look at the company in this video, discusses its financial situation, and points to some key trials coming up that will give investors a much better idea whether they should be jumping in on this stock.

Looking for more massive growth stocks in 2014?
They said it couldn't be done. But David Gardner has proved them wrong, time, and time, and time again, with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently, one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 06, 2014, at 8:00 PM, skeyewater wrote:

    I'm not really understanding the analysis that patients would prefer to take a pill every day or simply live their lives normally with a harmless amount of the virus circulating. In addition, the studies have shown over time that the engrafted cells continue to expand so the amount of virus which is consider at low enough levels that daily pills are not needed will go down over time. It sounds like an angle from a pharmacompany to try to hold onto their daily profits when a cure exists.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2867570, ~/Articles/ArticleHandler.aspx, 10/2/2014 3:08:04 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement